Skip to content

A randomized controlled trial of Sishun Tang in the treatment of migraine

A randomized controlled trial of Sishun Tang in the treatment of migraine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17013646
Enrollment
Unknown
Registered
2017-12-02
Start date
2018-01-01
Completion date
Unknown
Last updated
2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

test group:Sihun Tang
Control group:Placebo

Sponsors

Beijing University of Chinese Medicine Dongzhimen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. meet the Western medicine migraine (migraine with typical aura or aura migraine headache) diagnostic criteria. For clinical case of administration, migraine with aura only includes migraine with typical aura, and for other types of non-migraine headache with typical aura, typical headaches without headache, familial hemiparesis Headache, sporadic hemiplegia Migraine; 2. the first migraine attack age = 50 years old; 3. aged 18-65 years old; 4. signed informed consent; 5. patients for women; Note: intracranial organic diseases can not be excluded head CT scan to exclude intracranial organic diseases caused by headache.

Exclusion criteria

Exclusion criteria: 1. a month due to headache taking painkillers> 10 times; 2. In the first 3 months before enrollment, antipsychotics or antidepressants were used; 3. alcohol or other drug abusers; 4. merger of cardiovascular, cerebrovascular, liver, kidney, hematopoietic system and other serious primary diseases; 5. mentally ill patients; 6. Although headache, but as the symptoms of other diseases, such as hypertension, traumatic brain injury syndrome and intracranial organic disease; 7. allergic to the drug; 8. pregnant or lactating women; 9. basal migraine and other special types of migraine.

Design outcomes

Primary

MeasureTime frame
The number of headache attacks and the number of seizures by half rate;

Secondary

MeasureTime frame
Endothelin;Migraine was based on the patient-reported outcome rating scale;

Countries

China

Contacts

Public ContactBo Zhou

Beijing University of Chinese Medicine Dongzhimen Hospital

418095034@qq.com+86 18911244036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026